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Pulmonary Large Cell
Neuroendocrine
Carcinoma
A True High-Grade
Neuroendocrine Tumor
Needing Prospective
Therapeutic Data
To the Editor:
We read with interest the article by
Varlotto et al.1 on large cell neuroendo-
crine carcinoma (LCNEC) of the lung.
Based on Surveillance Epidemiology and
End Results (SEER) database, the authors
collected 1211 LCNEC cases (324 with-
out radiotherapy) and compared the clini-
copathologic and survival features of
LCNEC with those of 8295 (1120 without
radiotherapy) large cell carcinoma (LCC)
cases and 35,304 (355 without radiother-
apy) small cell lung cancer (SCLC) cases.
Briefly, the conclusion of this article is
that patients with LCNEC should be clas-
sified and treated as having a LCC rather
than a SCLC.
We would here take the position
that the results of this work do not entirely
justify the final statements and may raise
some confusion among oncologists.
First, diagnosis of LCNEC is dif-
ficult requiring a careful histopathologic
and immunohistochemical examination
on surgical specimens. Even in the
hands of expert pathologists, a major
agreement is achieved only in 40 to 50%
of cases.2 In a previous multi-institu-
tional experience with LCNEC, we orig-
inally selected 122 cases.3 Fifteen cases
were subsequently excluded because
LCNEC was combined with other tumor
types, and 24 cases were finally ex-
cluded because they lacked an unani-
mous diagnostic agreement among ex-
pert pathologists.3 For this reason, in our
opinion, a centralized pathological re-
view is necessary to confirm the diagno-
sis, a requisite that is lacking in the
article by Varlotto et al.1
Second, molecular and biomarker
analyses strongly support the fact that
LCNEC is very similar to SCLC, from
gene expression profiling to immunohis-
tochemical expression of neuroendo-
crine (NE) markers, p53, Rb, bcl-2,
Ki67/MIB-1, TTF-1, and several other
biomarkers along with apoptosis and
cell proliferation pathways.4,5
While LCNEC more often have a
clinical and radiologic presentation re-
sembling a non-small cell lung cancer
(NSCLC)/LCC (i.e., as a peripheral
mass), pooled analysis of therapy and
survival data seem to confirm that
LCNEC is an aggressive carcinoma with
a poor prognosis in stage I (about 40% at
5 years) and receiving a significant ben-
efit from pre-/postoperative chemother-
apy with cisplatin-based regimens.6,7
Response rate to platinum-based chemo-
therapy may reach about 80%, a figure
more similar to SCLC than LCC/
NSCLC.6
Curiously, all these data have not
been considered in the discussion sec-
tion in the article by Varlotto et al.1
The diagnosis of LCNEC requires
immunohistochemical or electron mi-
croscopy confirmation of neuroendo-
crine differentiation. Data reported by
Varlotto et al.1 on the increase from 8 to
21% of LCNEC diagnoses among LCC
likely reflect a wide and possibly not
appropriate use of immunostains for NE
markers in poorly differentiated NSCLC
(i.e., have pathologists used nonspecific
antibodies such as NSE or PGP9.5 to
identify NE differentiation?).
In conclusion, to our eyes, there is
a consistent body of evidence justifying
the classification of LCNEC as a true
high-grade NE carcinoma of the lung.
Further supporting this fact, identical
carcinomas have been recognized and
recently accepted in the new World
Health Organization classification of the
digestive tract among NE tumors.8
On the other hand, prospective clin-
ical data validating retrospective analyses
concerning the most effective therapeutic
approach for LCNEC are needed. By con-
trast, it is difficult to accept per se the
conclusions of the work by Varlotto et al.1
based on the absence of expert pathologic
review of the SEER cases.
Finally, from a pathologic view-
point, more stringent and objective cri-
teria on quoting the NE differentiation
(i.e., does a positive staining in more
than 10% of tumor cells for only one NE
marker represents a good cutoff in de-
fining a LCNEC?) are clearly required.
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